PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE

• Malin Hultcrantz,
• David Kleinman,
• Ravi Vij,
• Fernando Escalante,
• Michel Delforge,
• Nirali Kotowsky,
• Jacopo Bitetti,
• Natalie Boytsov,
• Leena Camadoo-O’byrne,
• Lindsey Powers Happ,
• Mujib Rohman,
• Guillaume Germain,
• Mei Sheng Duh,
• François Laliberté,
• Malena Mahendran,
• Ana Urosevic,
• Hans C. Lee

Affiliations

Malin Hultcrantz

1 Memorial Sloan Kettering Cancer Center, New York City, United States

David Kleinman

2 Flaum Eye Institute, University of Rochester Medical Center, Rochester, United States

Ravi Vij

3 Washington University, St. Louis, St. Louis, United States

Fernando Escalante

4 Hematology Department, University Hospital of Leon, Leon, Spain

Michel Delforge

5 Catholic University of Leuven, Leuven, Belgium

Nirali Kotowsky

6 GSK, Upper Providence, United States

Jacopo Bitetti

7 GSK, Zug, Switzerland

Natalie Boytsov

6 GSK, Upper Providence, United States

Leena Camadoo-O’byrne

8 GSK, Stevenage, United Kingdom

Lindsey Powers Happ

9 GSK, Collegeville, United States

Mujib Rohman

10 GSK, Windsor, United Kingdom

Guillaume Germain

11 Groupe d’Analyse, Ltée, Montreal, Canada

Mei Sheng Duh

12 Analysis Group, Boston, United States

François Laliberté

11 Groupe d’Analyse, Ltée, Montreal, Canada

Malena Mahendran

11 Groupe d’Analyse, Ltée, Montreal, Canada

Ana Urosevic

11 Groupe d’Analyse, Ltée, Montreal, Canada

Hans C. Lee

13 Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, United States